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AbstrACt
Introduction Guidelines concerning the follow-up of 
subjects occupationally exposed to lung carcinogens, 
published in France in 2015, recommended the setting up 
of a trial of low-dose chest CT lung cancer screening in 
subjects at high risk of lung cancer.
Objective To evaluate the organisation of low-dose chest 
CT lung cancer screening in subjects occupationally 
exposed to lung carcinogens and at high risk of lung 
cancer.
Methods and analysis This trial will be conducted in 
eight French departments by six specialised reference 
centres (SRCs) in occupational health. In view of the 
exploratory nature of this trial, it is proposed to test initially 
the feasibility and acceptability over the first 2 years in 
only two SRCs then in four other SRCs to evaluate the 
organisation. The target population is current or former 
smokers with more than 30 pack-years (who have quit 
smoking for less than 15 years), currently or previously 
exposed to International Agency for Research on Cancer 
group 1 lung carcinogens, and between the ages of 55 and 
74 years. The trial will be conducted in the following steps: 
(1) identification of subjects by a screening invitation 
letter; (2) evaluation of occupational exposure to lung 
carcinogens; (3) evaluation of the lung cancer risk level 
and verification of eligibility; (4) screening procedure: 
annual chest CT scans performed by specialised centres 
and (5) follow-up of CT scan abnormalities.
Ethics and dissemination This protocol study has been 
approved by the French Committee for the Protection of 
Persons. The results from this study will be submitted to 
peer-reviewed journals and reported at suitable national 
and international meetings.
trial registration number NCT03562052; Pre-results.
IntrOduCtIOn  
Lung cancer was the most common newly 
diagnosed cancer in 2012 with 1.8 million 
new cases worldwide. It is also the leading 
cause of cancer death, responsible for 
approximately one out of every five cancer 
deaths.1 In addition to smoking, occupational 
exposure to carcinogens constitutes another 
major risk factor for lung cancer. Several 
carcinogenic agents and exposure situations 
have been classified as definite carcinogens 
by the International Agency for Research on 
Cancer (IARC) (group 1) and associated with 
an increased lung cancer incidence: asbestos, 
arsenic and arsenic compounds, benzo(a)
pyrene, beryllium and beryllium compounds, 
bis(chloromethyl) ether and chloromethyl 
methyl ether, cadmium and cadmium 
compounds, hexavalent chromium deriva-
tives, diesel engine emissions, sulfur mustard, 
strengths and limitations of this study
 ► This study will test the feasibility and acceptability of 
CT lung cancer screening in smoking subjects occu-
pationally exposed to lung carcinogen.
 ► Target population is subjects at high  risk of lung 
cancer with expected favourable benefit-risk bal-
ance according to previous screening programmes 
in smoking subjects.
 ► Current smokers will be encouraged to enter a 
smoking cessation programme and smoking cessa-
tion will be evaluated.
 ► This study will assess the incremental cost-effec-
tiveness ratio of this screening programme.
 ► Target population is not directly identifiable from 
databases. All subjects aged 55–74 years need to 
be invited initially for evaluation of eligibility to the 
screening programme (according to the level of 
cumulative smoking and exposure to occupational 
carcinogens).
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coal tar, coal tar pitch, soot, coal gasification and coke 
production, work in iron and steel foundries, certain 
nickel derivatives, plutonium-239, radon-222, X-rays and 
gamma rays and daughter products (work in iron ore 
mines), crystalline silica, the painting profession, tobacco 
smoke second hand, talc containing asbestiform fibres, 
aluminium production using the Söderberg process, the 
rubber industry and welding fumes.
The National Lung Screening Trial (NLST) (USA)2 
demonstrated the efficacy of annual chest CT screening 
in populations of smokers (30 pack-years or more) or 
former smokers who have quit smoking for less than 15 
years, with 30 pack-years or more. Following the NLST 
publication, guidelines and expert opinions have been 
published all over the world.3–12 The majority of these 
guidelines recommend low-dose chest CT lung cancer 
screening, but under strictly controlled conditions. 
In France, in 2014, a task force commissioned by the 
French National Authority for Health (HAS) conducted 
a review of the literature on the efficacy, acceptability 
and safety of low-dose chest CT lung cancer screening 
and concluded that the level of proof was insuffi-
cient to recommend a national lung cancer screening 
programme, as the benefit-risk balance was unknown.13 
The most recent review of the literature on lung cancer 
screening, published in 2016, reached a similar conclu-
sion that the benefit-risk balance of low-dose chest CT 
screening has not been correctly documented.14 This 
benefit-risk balance can be improved in various ways, 
especially by decreasing the number of false-posi-
tives and by optimising the selection of subjects likely 
to benefit from screening. The benefit-risk balance 
becomes increasingly more favourable when higher 
proportions of subjects at high risk of lung cancer are 
included in screening programmes.3–12
A recent systematic meta-analysis reviewing all cohort 
studies involving chest CT screening in former asbes-
tos-exposed workers showed that chest CT-based lung 
cancer detection rates among asbestos-exposed workers 
were at least equal to the prevalence observed in heavy 
smokers.15 CT screening in asbestos-exposed workers 
appears effective to detect asymptomatic lung cancer 
and identifies a proportion of stage I cancers similar to 
that detected in smokers. The authors concluded that 
CT screening of asbestos-exposed workers could decrease 
mortality to a similar degree to that observed in heavy 
smokers and should therefore not be neglected, particu-
larly in individuals co-exposed to tobacco.
In 2015, French national guidelines recommended an 
experiment of low-dose chest CT lung cancer screening in 
subjects currently or previously occupationally exposed to 
lung carcinogens (expert consensus). Based on a review 
of the literature, this recommendation defined a target 
population in which the level of lung cancer risk was at 
least equivalent to or greater than that of the NLST trial 
population.16
We present the protocol of this study in this paper.
ObjECtIvEs
The primary objective was to evaluate the organisation 
of low-dose chest CT lung cancer screening in subjects 
currently or previously occupationally exposed to lung 
carcinogens.
The secondary objectives were
 ► To describe the population recruited in each step of 
the protocol.
 ► To develop a tool to identify subjects exposed to 
pulmonary carcinogens and with high risk of lung 
cancer.
To evaluate the impact of the proposed screening 
programme on smoking cessation at 1, 2 and 3 years.
On the population of workers who were identified as 
being at high risk of lung cancer and for whom low-dose 
chest CT lung cancer screening is available:
 ► To evaluate the medical impact of low-dose chest CT 
scan.
 – Measurement of medical irradiation induced by the 
screening programme (CT dose delivery at screen-
ing and of additional radiological interventions).
 ► To evaluate the social impact of the screening 
programme.
 – Description of the medical and health insurance 
formalities completed at the time of screening: 
occupational disease notification, submission of 
a compensation application to the Fonds d'Indem-
nisation des Victimes de l'Amiante (FIVA) (French 
Asbestos Compensation Fund). These medical 
and health insurance formalities will concern lung 
cancers detected by screening and also benign 
asbestos-related pleural or pulmonary diseases 
(particularly pleural plaques which are the most 
common disease after asbestos exposure).
 ► To conduct a cost-effectiveness analysis of the 
programme.
MEthOds And AnAlysIs
The study is a multidepartment, prospective, descriptive 
study, organised into six work packages (WP) (figure 1):
 ► WP1: Methodology—epidemiology.
 ► WP2: Evaluation of occupational exposure.
 ► WP3: Imaging.
 ► WP4: Lung cancer follow-up strategy.
 ► WP5: Smoking cessation.
 ► WP6: Medical consumption analysis.
Six specialised reference centres (SRCs) in four 
different regions will recruit about 200–600 eligible 
subjects per year and per region.
Each of these centres possesses the four essential 
prerequisites: an occupational health clinic, radiology 
team with specific chest imaging skills, pulmonology team 
or network of pulmonologists specialised in lung cancer 
and smoking cessation team.
In view of the complexity of this organisation, it is 
proposed to test initially the feasibility and acceptability 
of the screening programme sequentially for the first 
2 years in two SRCs and to extend the study to the other 
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SRCs after 2 years (figure 2). The feasibility will be evalu-
ated by the rate of detected lung cancer and the propor-
tion of lung cancer detected with the chest CT scan 
programme in subjects exposed to occupational carcin-
ogens. The acceptability will be evaluated by the propor-
tion of subjects undergoing repeated low-dose chest CT 
screening among eligible responders during the first 
phase of the study (the first 2 years).
In these two departments, the population aged between 
55 and 74 years was estimated to be about 5 00 000 in 
2015 by the French statistics institute (INSEE). Ad hoc 
adjustments will be decided for the creation of SRCs in 
the third year on the basis of the data acquired in the 
two pilot departments, especially on the expected target 
population participation rate.
Eligibility criteria
Inclusion criteria: Subjects at high risk of lung cancer, as 
defined in the occupational health surveillance guide-
lines for subjects currently or previously exposed to lung 
carcinogens based on an expert consensus (table 1).
Exclusion criteria are the presence of clinical signs of 
lung cancer, subjects with a history of lung cancer, pres-
ence of serious short-term life-threatening comorbidities, 
absence of occupational exposure to lung carcinogens 
according to the predefined criteria, subjects already 
included in another prospective cohort study, subjects 
already assessed by chest CT scan during the previous 
year, no tobacco exposure or insufficient tobacco expo-
sure (<10, <20 or<30 pack-years according to the level of 
cumulative exposure to different occupational carcino-
gens as stated in table 1) or smoking cessation for more 
than 15 years.
study procedure
Study procedure is described in figure 3.
Step 1: Identification of subjects currently or previously 
occupationally exposed to lung carcinogens
All healthcare actors of a targeted geographical territory 
(general practitioners, occupational health physicians, 
pulmonologists, radiologists and health insurance funds) 
and concerned by the study will receive detailed informa-
tion about setting up of the project. Workers’ representa-
tives and patients' associations will also be informed about 
setting up of the project.
In a given department, screening invitation letters will 
be sent by the cancer screening centre to subjects between 
the ages of 55 and 74 years by monthly waves over a 2-year 
period from September 2018.
The invitation letter will comprise an information sheet 
describing the lung cancer screening eligibility criteria 
and a simplified, two-page, self-administered question-
naire (AQ1) including questions about all previous jobs 
during complete working life (professional calendar) 
and exposure to non-occupational risk factors, especially 
Figure 1 Work packages (WP) and specialised reference centre (SRC) organisation for the LUCSO.
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smoking. This questionnaire will be returned to each 
SRC and analysed by a clinical research associate (CRA) 
and, if necessary, by an industrial hygienist. A letter will 
be sent to ineligible subjects to explain that lung cancer 
screening is not recommended in their case. Subjects 
presenting a high probability of occupational exposure 
to lung carcinogens will be invited to attend the occupa-
tional health clinic. Subjects reporting uncertain expo-
sure to lung carcinogens will be asked to fill in and return 
a more detailed personalised self-administered question-
naire (AQ2) to each SRC.
Step 2: Evaluation of occupational exposure
After evaluation of occupational exposure from AQ2, 
subjects with high probability of occupational exposure 
will be invited to the occupational health clinic. A letter 
will be sent to subjects considered to be ineligible for 
screening, informing them that lung cancer screening 
is not recommended in their case. A smoking cessation 
consultation will be proposed to the subjects contacted, 
when appropriate.
Step 3: Evaluation of the lung cancer risk level and verification of 
eligibility
As shown in table 1, subjects will be classified into the 
following groups:
 ► Ineligible for screening (insufficient cumulative expo-
sure to occupational carcinogens, insufficient cumu-
lative smoking and/or presence of exclusion criteria). 
A letter will be sent to the attending physician or to 
the occupational health physician indicating the most 
appropriate procedure.
 – Smokers must be encouraged to enter a smoking 
cessation programme
 – Postemployment or postexposure surveillance of 
asbestos-exposed workers must be conducted ac-
cording to French recommendations.17
 – Prevention procedures for subjects still at work, 
especially when potentially persistent carcinogen 
exposure is identified.
All ineligible subjects will be followed up at 1, 2 and 
3 years by contacting the general practitioner with the 
subject’s consent in order to collect data on chest imaging, 
occurrence of lung cancer and smoking status.
Figure 2 Project phases: recruitment and follow-up calendar.
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Step 4: Screening procedure
Eligible subjects will receive detailed information, espe-
cially concerning the risk of detecting abnormalities 
on CT scan, overdiagnosis and the risks of radiation 
exposure.
Active smokers will be encouraged to enter a smoking 
cessation programme.
Pulmonary function tests will be performed at inclu-
sion. Low-dose chest CT scan will be performed at inclu-
sion, then annually for 2 years (ie, T0, T1, T2). Chest 
CT scans will be performed with the Maximum Intensity 
Projection (MIP) reconstruction images and the imple-
mentation of a computer-aided detection software by 
radiologists specialised in chest imaging according to the 
technical conditions and interpretation guidelines estab-
lished by the coordinating centre (see online supple-
mentary file 1). The use of additional methods, such as a 
computer-assisted detection (CAD) system, will be left to 
the discretion of each centre.
Step 5: Lung cancer follow-up strategy
Only nodules and masses detected on CT screening will 
be considered to be positive findings. Lesions will be clas-
sified according to the British thoracic society guidelines18 
and patients managed according to the European paper 
recommendations.19 Subjects presenting other radiolog-
ical abnormalities on CT should be referred for specific 
management (particularly benign asbestos-related pleural 
abnormalities, which may be eligible for specific workers’ 
compensation in France). The proposed diagnostic and 
Table 1 Definition of subjects at high risk for lung cancer 
between the ages of 55 and 74 years for a cumulative 




of exposure* or 
disease
Active or former 
smoking, after 
quitting for less 
than 15 years
Asbestos Intermediate ≥30 PY 
High† ≥30 PY 
High‡ ≥20 PY 
Asbestosis ≥20 PY 








≥ 3  carcinogenic 
agents 
≥ 10 PY 
Adapted to Delva et al16
Special cases: Crystalline silica (silicosis is necessary to integrate 
the high-risk group for lung cancer, independently of the duration 
of exposure); diesel engine exhaust fumes (a high level of exposure 
defined by employment in underground mines, tunnel construction 
or underground mine maintenance is necessary to integrate the 
high-risk group for BPC).
Intermediate exposure: All other documented significant 
occupational exposure situations. The majority of these situations 
involve intervention on materials or equipment likely to discharge 
asbestos fibres.
*From the definition of the jury of the 1999 French consensus 
conference on the follow-up of asbestos-exposed workers: 
High exposure: Confirmed, high and continued exposure for 
a duration equal to or in excess of 1 year; examples: working 
in the manufacture or transformation of materials including 
asbestos and their equivalents during intervention on materials or 
equipment likely to discharge asbestos fibres (eg,: fireproofing, 
naval construction); Confirmed, high and discontinued exposure 
of a duration equal to or in excess of 10 years (eg,: mechanics/
machine operators on heavy goods vehicle brake systems, cutting 
of asbestos cement).
†Cumulative exposure duration <5 years.
‡Cumulative exposure duration ≥5 years.
§aluminium production, coal gasification, coal tar pitch, coke 
production, X-rays and gamma rays, radon, iron ore mines, 
plutonium, steel foundries, the painting profession, rubber 
production, chromium(VI) compounds, beryllium, cadmium and its 
compounds, bis(chloromethyl) ether, chloromethyl methyl ether, 
metal cobalt with tungsten carbide and welding fumes.
Figure 3 Organisation of lung cancer screening in subjects 
at high risk of lung cancer in France.
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treatment options are presented in online supplementary 
file 2 .
smoking cessation (WP5)
In the context of this protocol, subjects referred for 
smoking cessation will be evaluated and managed 
according to the HAS guidelines revised in October 
2014.20 At least, the following parameters will be recorded:
 ► Smoking history (especially age of first cigarette and 
age of daily smoking).
 ► Number of cigarettes per day.
 ► Cumulative exposure expressed as the number of 
pack-years.
 ► Nicotine dependence by the simplified two-ques-
tion Fagerström test and determination of carbon 
monoxide (CO) in expired air.
 ► The smoker’s motivation to quit smoking.
 ► Comorbid anxiety and depression by the Hospital 
Anxiety and Depression scale.21
 ► Associated co-consumptions (especially alcohol and 
cannabis).
 ► The subject's weight will be recorded at this first visit.
Initial management will be based on motivational inter-
viewing techniques designed to adapt management to the 
subject's level of motivation and, if necessary, the smoking 
cessation drug treatments recommended to relieve 
smoking withdrawal symptoms and prevent relapse.
The subject's smoking status will be investigated at 
follow-up (abstinence, decreased smoking or status 
quo). Any difficulties encountered by the subject will be 
recorded (occasional smoking, cravings). Determina-
tion of carbon monoxide in expired air will be used to 
confirm the smoking status declared by the subject. The 
efficacy of treatment and its adverse effects will be eval-
uated. Dose adjustment or change of treatment can be 
performed when necessary. The subject’s weight curve 
will be recorded.
At the end of the first and subsequent follow-up visits, 
the subject will be systematically invited to attend another 
follow-up visit as long as necessary. The same data will be 
collected at each follow-up visit.
In the context of the present protocol, the subject's 
smoking status will be investigated at each step of the lung 
cancer screening programme.
Cost-effectiveness analysis (WP6)
The aim of this WP is to prospectively assess the incre-
mental cost-effectiveness ratio of this screening 
programme on the basis of real-life data obtained 
during the project. More specifically, the costs of the 
programme, the number and stages of lung cancer diag-
nosed by the programme, the life-years gained and the 
quality-adjusted life-years will be analysed. Underlying 
and contributing causes of death recorded on the death 
certificate will be obtained. The main assumptions for 
this cost-effectiveness analysis were: screening does not 
affect the life expectancy of participants in whom lung 
cancer is not diagnosed. For participants not known to 
have died at the end of the programme, we will estimate 
the beyond-trial life-years on the basis of their age at the 
date of last news, gender, smoking status and lung cancer 
stage, using French life tables adjusted for smoking status 
and stage-specific annual probabilities of dying from lung 
cancer. Health state utility will be assessed by economic 
analysis and will be limited to direct costs, with a lifetime 
horizon, from the social security perspective. This analysis 
will incorporate 4% discount per year.
Direct costs include: programme costs, costs to assess 
subject eligibility, organisation costs (data management, 
subject’s invitation, general practitioner information, 
meetings, etc), costs of smoking cessation interventions, 
costs of CT scan, costs of lung cancer management, costs 
of false-positive results.
To assess the possibility of generalising our results, 
sensitivity analysis will be performed with the following 
parameters: effectiveness of screening, by varying the 
rate of lung cancer detected, by varying the rate of lung 
cancer without screening programme in this high-risk 
population, early diagnosis (by varying the distribu-
tion with screening), median survival by stage, cost of 
screening organisation, lung cancer management costs, 
CT screening cost, cost of consultation to assess occupa-
tional exposure.
EndPOInts
The primary objective of this study is to evaluate the 
feasibility of a complex screening programme. The 
primary endpoint for the first 2 years will therefore be 
the 2-year screening coverage rate at the two-pilot SRCs. 
This screening coverage rate will be determined by the 
proportion of subjects undergoing low-dose chest CT 
screening among all eligible subjects. The following 
procedure quality indicators will be studied: validity of 
the procedure in terms of response rate and identifica-
tion of eligible exposed subjects prior to extension of the 
screening programme.
The main evaluation over the 7-year period will focus 
on the following indicators:
 ► Examination quality indicator: lung cancer detection 
rate, lung cancer detection rate by stage.
 ► Follow-up indicator: proportion of subjects who quit 
smoking at each step of screening, mortality rate, and 
among non-screened subjects, but attending the occu-
pational health clinic: mortality rate, lung cancer rate, 
lung cancer rate.
Other endpoints will also be studied:
 ► Impact of the screening campaign
 – Percentage of subjects accepting to participate in 
the entire screening programme.
 – Percentage of subjects lost to follow-up (1-
year, 2-year follow-up, other complementary 
investigations).
 ► Evaluation of occupational exposure and medical-so-
cial consequences
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 – Validity of the self-administered questionnaire 
(AQ1) and the detailed self-administered question-
naire (AQ2) for evaluation of occupational expo-
sure in the context of this screening programme 
but only among subjects who will come to occupa-
tional health clinic.
 – Number of notified cases of occupational disease 
asking for compensation (for lung cancer or other 
asbestos-related occupational disease mainly pleu-
ral plaques, pleural visceral fibrosis or asbestosis) 
following results of CT scan.
 ► Lung cancer follow-up strategy
 – Proportion of invasive diagnostic procedures (fi-
broscopy, puncture under scanner, mediastinosco-
py and surgery).
 – Proportion of non-invasive diagnostic procedures 
(CT scan, PET scan).
 – Proportion of serious and non-serious adverse ef-
fects related to screening. Serious and non-serious 
adverse effects are presented in online supplemen-
tary file 3.
 ► Health economic analysis
 ► Study of time intervals
 – Intervals between each step of screening (eval-
uation of exposure, referral to the occupation-
al health clinic, inclusion, various follow-up 
examinations).
Calculation of the number of participants
Estimation of the number of subjects likely to be eligible 
for the study was based on the results of the ICARE study 
for the single carcinogen, asbestos and for tobacco.22 The 
number of potentially eligible subjects is 11 000 subjects 
for the age-groups and levels of exposure concerned by 
lung cancer screening and for the departments concerned 
by the study. In the NLST trial, 1.1% of lung cancers were 
diagnosed by the first screening CT scan in the low-dose 
chest CT group.2 The proposed study will target a popu-
lation at higher risk of lung cancer, in which a higher 
rate of lung cancer is expected. Response rate in lung 
cancer screening is estimated around 30%.23 If low-dose 
chest CT scan is performed in 3000 subjects on inclusion 
in this study, we will be able to demonstrate a significant 
difference of 0.5% in lung cancer detection rates between 
this study (1.8%) and the NLST trial (1.1%) with power 
statistics of 90%.
Impact of the pilot study
This French pilot lung cancer screening programme is 
designed to test the feasibility of organised lung cancer 
screening in a population of subjects occupationally 
exposed to lung carcinogens and tobacco in two depart-
ments. Data from this pilot study will be necessary to 
envisage possible extension to six other departments and 
then to all of France. The acceptability of the screening 
programme by the target population constitutes one of 
the prerequisites for implementation of a nationwide 
screening programme.24
Patient and public involvement
The development of the research question and outcome 
measures and the design of the study were developed 
without patients. However, before patient’s inclusion, 
workers’ representatives and patients' associations will 
be informed about setting up of the project. Information 
letter on the study results will be sent to participants.
Ethics and dissemination
The research results will be published in peer-reviewed 
national and international journals and presented at 
national and international conferences. Data curation 
will be 10 years.
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